Japan Panel Oks Clinical Study on Transfusions of iPS Cell-Made Platelets
Newsfrom JapanSociety Lifestyle
Tokyo, Sept. 21 (Jiji Press)--A Japanese health ministry panel approved Friday a clinical research plan by a Kyoto University team to infuse platelets made from induced pluripotent stem cells into an intractable blood disease patient.
The team plans to transfuse the platelets, which work to stop bleeding, into the sufferer of aplastic anemia, who cannot produce enough blood cells, within a year.
To create the platelets, Koji Eto, the university's professor, and colleagues will use iPS cells, which theoretically can develop into almost all types of tissue, made from the patient's own mature cells.
In the one-year clinical study, the researchers will infuse some 140 billion platelets in a total of three transfusions and check the safety and effectiveness of the therapy. They have already picked the patient and plan not to recruit more.
Infusions of donated platelets are now available for aplastic anemia patients. But this treatment cannot be used for patients, like the one picked by the research team, who tend to show strong rejection reactions to blood cells of other people.
[Copyright The Jiji Press, Ltd.]